Boston Scientific Corporation Common Stock

Afficher le graphique complet Full chart

Financials

Total de l'actif 30.78 B32.23 B32.47 B35.14 B39.4 B43.67 B Total du passif 15.45 B16 B15.24 B17.22 B18.93 B19.65 B Total des capitaux propres 15.33 B16.62 B17.57 B19.53 B22 B24.47 B Total du passif et des capitaux propres 30.78 B32.23 B32.47 B35.14 B39.4 B43.67 B Dette totale —————— Dette nette ——————

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Nouvelles

Zscaler, AutoZone et Regencell font partie des 10 plus grands perdants de la semaine dernière (25 mai - 29 mai) : sont-ils présents dans votre portefeuille ? | Benzinga France

BSX

Financials